Object. Coagulopathy and thrombocytopenia are common after traumatic brain injury (TBI), yet transfusion thresholds for mildly to moderately abnormal ranges of international normalized ratio and platelet count remain controversial. This study evaluates associations between fresh frozen plasma (FFP) and platelet transfusions with long-term functional outcome and survival in TBI patients with moderate hemostatic laboratory abnormalities.
T hrombocyTopenia and coagulopathy commonly complicate the hospital course for patients who have sustained a TBI. The incidence of these 2 hemostatic abnormalities increases as the severity of head injury increases. 13 For example, blood coagulation disorders have been reported in 15%-30% of all patients with TBI and in more than 60% of patients with severe TBI. 20 Incidences of thrombocytopenia and coagulopathy appear to be approximately equal in cases of TBI; in a study of moderate to severe TBI, 46% of patients experienced thrombocytopenia and 41% experienced coagulopathy.
Bleeding diathesis is associated with the development of many secondary complications, leading to a poorer outcome in patients with TBI. Intracranial hemorrhage is the most devastating complication of thrombocytopenia and coagulopathy in this population. Patients who have sustained TBI and have platelet counts less than 100 × 10 9 /L, INRs greater than 1.3, or PTTs longer than 35 seconds have higher rates of progression of intracranial hemorrhage than patients for whom these values are normal. 1 This association is especially troubling because intracranial hemorrhage can rapidly increase intracranial pressure, expose neural tissue to the toxic components of blood, and is associated with increased mortality in patients with severe TBI. 1 Other secondary complications associated with coagulopathy include cerebral ischemia, brain edema, delayed traumatic intracerebral hematoma, and ARDS. 7 The development of TBI-associated coagulopathy is also associated with a longer ICU stay and an almost 10-fold increased risk of death. 21 Transfusion of platelets or FFP could correct thrombocytopenia or coagulopathy, respectively, and potentially decrease the risk of developing secondary complications. However, risks of platelet and FFP transfusions must be weighed against unproven benefits of correction of these laboratory abnormalities. Several studies provide empirical evidence illustrating the serious complications of platelet and FFP transfusion. For example, although many blood products are associated with TRALI, plasma-rich components such as apheresis platelets and FFP are most commonly implicated. 19, 22 This association is important to note as TRALI is currently the leading cause of transfusion-related morbidity and mortality in the US. 22 Transfusion of FFP in patients who have suffered a TBI is independently associated with a greater risk of developing multiple organ failure and ARDS; platelet transfusion did not share this association. 25 Additionally, transfusion of either of these products carries standard transfusion risks such as other immune reactions, infection, and TACO. 19 Thrombocytopenia, coagulopathy, and anemia and the transfusions used to treat them carry risks that must be weighed against each other. While there is some evidence that RBC transfusion may ultimately be harmful in moderate anemia, no study has shown how transfusion of platelets and FFP affects long-term functional outcome in TBI patients with moderately low platelet counts or moderately high INRs. Transfusion is most likely beneficial in cases of more extreme bleeding diathesis but has been shown to be harmful in TBI patients without laboratory evidence of coagulopathy. 7 Between these two extremes, clinical equipoise exists for TBI patients with moderate degrees of thrombocytopenia and coagulopathy.
The purpose of this study is to assess the effects of platelet and FFP transfusions on long-term functional outcome in TBI patients with moderate thrombocytopenia and coagulopathy. The study also includes the effects of RBC transfusion in TBI patients with moderate anemia in an effort to confirm previous results with a larger sample size.
Methods
This retrospective study consists of an analysis of prospectively collected data from 3 different databases. The TBI database includes data from a subset of patients enrolled in an ongoing prospective observational study concerning the role of genetics in functional recovery after TBI. Between January 2005 and December 2009, patients were admitted with TBI to Parkland Memorial Hospital, a large urban Level I trauma center, and were referred to the neurosurgery service. Patients were included if brain injuries were confirmed by the presence of abnormal neuroimaging or a postresuscitation GCS score less than 13. Patients were excluded if they were younger than 14 years of age or had a history of dementia or prior CNS disease. Clinical and laboratory information was obtained from the Parkland Memorial Hospital clinical data repository, and blood component transfusion data were obtained from transfusion service records during the inpatient hospital stay.
The TBI database includes information such as age, sex, and length of hospital stay. This database also includes parameters concerning initial injury severity including admission GCS score, ISS, head AIS, face AIS, neck AIS, and TCDB score. Anatomical severity of TBI was rated on CT scans using the classification scheme developed through the TCDB. This is a 6-part ordinal scale as follows: 1) Diffuse Injury I (no intracranial pathology); 2) Diffuse Injury II (cisterns present with midline shift 0-5 mm, no high or mixed-density lesions > 22 cm , not surgically evacuated). The TCDB CT Classification Scale has been widely used in TBI studies, and trained examiners can reliably rate the scans. It has been shown to be a highly statistically significant predictor of mortality and outcome in patients with severe TBI.
14 Patients were not directly stratified for specific injury type (for example, contusion or intracranial hemorrhage) but measures of physical effects on the brain (for example, TCDB score) and severity of initial injury (for example, GCS score or ISS) were recorded and compared between patients who received transfusions and those who did not. At approximately 6 months after injury, GOSE scores, FSE scores, and survival were evaluated and recorded in the TBI database.
Volumes of transfused platelets, FFP, packed RBCs, albumin, cryoprecipitate, and recombinant factor VIIa were obtained from Transfusion Service records. The daily highest and lowest laboratory values were recorded as available from the clinical data repository until hospital discharge or up to 28 days after injury. Laboratory parameters recorded included arterial pO 2 , arterial pH, D-dimer, fibrinogen, HCT, hemoglobin, INR, PTT, platelet count, serum sodium, and serum glucose.
The primary measure of long-term functional outcome was performance on the GOSE approximately 6 months after injury. The GOSE is an objective measure of physical and cognitive function after TBI on an 8-point ordinal scale. 26 A score of 1 on the GOSE corresponds to death and a score of 8 corresponds to good functional recovery with different degrees of functional disability in between. The FSE score, an additional measure of functional outcome, also evaluates physical and cognitive disability but with more detailed parameters such as social integration on a 41-point ordinal scale. 5 Converse to the GOSE, a higher score on the FSE corresponds to worse functional outcome. Survival, the final measure of outcome, was recorded at the time of follow-up.
Follow-up interviews to obtain outcome scores were performed either in person or by telephone. Interrater reliability for GOSE and FSE scores was assessed by auditing 20% of the scoring sheets every 3 months. Reproducibility was greater than 99%. All outcome interviews and scoring of the GOSE and FSE were conducted by 1 of 3 study coordinators over a period of 5 years. Each rater had at least a bachelor's level education and at least 1-month experience in working with TBI patients. Each was trained by a neurologist by observing in-person administration of at least 5 patients, as well as by over-thetelephone administration for 5 patients. Structured questionnaires were used during the follow-up interviews. 5, 11, 26 Each patient was interviewed only once.
Moderate ranges for thrombocytopenia, coagulopathy, and anemia were defined using our collected laboratory data. The lowest recorded values of platelet count, INR, and HCT were divided into deciles. Percentile ranges in which approximately half of patients received the appropriate transfusions of platelets, FFP, or packed RBCs, respectively, were chosen as the moderate ranges. Using this method, moderate thrombocytopenia was defined as platelet counts between 50 × 10 9 /L and 107 × 10 9 /L, moderate coagulopathy as an INR between 1.4 and 2.0, and moderate anemia as HCT between 21% and 30%. We inferred that clinical equipoise existed in these ranges, in which only half of the patients received transfusions, and thus these ranges were ideal for study.
The means and standard deviations for continuous and discrete variables were compared between the subgroups of patients who underwent transfusion and those who did not by using independent 2-sample Student ttests for normally distributed data and Mann-Whitney U-tests for nonnormally distributed data. Mortality rates were compared using a 2-sided Fisher exact test. Univariate Spearman correlations were used to determine associations between continuous, discrete variables and functional outcome measures. A rank biserial correlation was used to assess associations between receiving a type of transfusion and functional outcome. An ordinal regression model was used to determine odds ratios of having a worse functional outcome score in each of the transfused subgroups compared with a nontransfused subgroup. Logistic regression was used to determine the odds ratios of higher mortality rates between these same groups. Variables were included in the regression models if they correlated significantly with outcome measures in univariate analysis and resulted in a significant drop in deviance in a backward selection process. Statistical analyses were performed using SPSS (version 18.0, SPSS, Inc.), and the R statistical computing language (www.r-project.org). For all analyses a p value < 0.05 defined significance.
Results
Of the patients who had consented to be in the study, 71.2% had follow-up interviews. Of patients with followup information, transfusion data could not be obtained for 15% of patients as transfusion data from before October 2005 had been purged, and 1% of patients had other missing data variables; these patients were removed from the study. After the exclusion of these patients, 480 patients with complete data remained. Table 1 shows demographic and transfusion types received by these patients with complete data.
Patients who were excluded due to a lack of transfusion data (that is, patients enrolled before October 2005) were not systematically different from those with transfusion data; they at one time did have recorded data but these data were purged before we could access them. The purge of data before October 2005 was not related to our study or to any patient characteristics other than the fact that these data had been determined to be too old to keep by persons outside our group who were maintaining this separate transfusion database. Other patients lost to fol- low-up were not believed to be systematically different from those who had follow-up. Of these 480 patients, 88 (18.3%) had moderate thrombocytopenia, 82 (17.1%) had moderate coagulopathy, and 211 (44.0%) had moderate anemia ( Table 2 ). All subsequent analyses focus on these patients with moderate deficiencies, as about half in each moderate subgroup underwent transfusions and half did not, seemingly representing clinical equipoise. Tables 3 and 4 compare demographics, initial injury severity measures, inpatient characteristics, and outcome measures for moderate coagulopathy and moderate thrombocytopenia subgroups, respectively. Patients with moderate coagulopathy who received FFP had significantly poorer GOSE and FSE scores, indicating a poor long-term functional outcome although there was no significant difference in initial injury severity measures. Conversely, patients with moderate thrombocytopenia who received platelets had worse ISSs but did not have significantly different GOSE or FSE scores compared with patients who did not receive platelets. Similar analysis comparing variable means in moderate anemia was performed but is not reported, as it simply confirms results generated by Warner et al. 24 in that patients who underwent a transfusion had a worse admission GCS score, lower recorded lowest HCT, more days with low HCT, a longer hospital stay, and a poorer long-term functional outcome as measured by the GOSE and FSE. The current analysis includes the 139 patients reported on in our earlier publication, 24 as FFP and platelet transfusion were not addressed in that study.
Univariate correlations revealed that several demographic features, initial ISSs, and inpatient laboratory parameters correlated significantly with worse functional outcome and survival. Tables 5 and 6 show statistically significant correlations of these variables with outcome measures for the moderate coagulopathy and thrombocytopenia subgroups, respectively (moderate anemia subgroup results are not shown here, as they were similar to results in our previous study). 24 The following variables were significantly correlated with poorer outcome as determined by GOSE and FSE scores: transfusion with platelets, plasma, or packed RBCs; TCDB score; abnormal arterial pH; serum sodium abnormalities; and hematological abnormalities such as low platelet count or high INR. Transfusion with plasma, abnormal arterial pH, abnormal serum sodium, low platelet count, and high INR also correlated negatively with survival. Higher GCS scores, indicating less severe initial injuries, correlated positively with both outcome and survival.
Patient age, initial GCS score, and highest recorded serum sodium were included in the ordinal regression model as they had significant correlation with outcome and resulted in significant decreases in deviance in a backward selection process. Results of ordinal regression are shown in Tables 7-9 and Fig. 1 . Interestingly, ISS was not selected in backward selection and thus was not included. The ISS also did not have any statistically significant univariate correlations with any outcome measures, whereas GCS score significantly correlated with GOSE scores, FSE scores, and mortality, suggesting that GCS score may be a better predictor of outcome than ISS. In the moderate coagulopathy subgroup, the OR of patients who received an FFP transfusion and had a lower GOSE score relative to those who did not was 5. 
Discussion

Transfusion in Moderate Coagulopathy
In patients with TBI and moderate coagulopathy, FFP transfusions were associated with poorer long-term functional outcomes as measured using the GOSE. In this moderately coagulopathic group, there also appears to be a synergistic negative effect on outcome in patients receiving FFP and RBCs, both of which are implicated in increasing the risk of complications. Platelet transfusion in patients with moderate thrombocytopenia was not significantly associated with outcome either positively or negatively. Additionally, this study confirms previous findings by our group; 24 in this larger study population of patients with TBI, RBC transfusions were similarly associated with poor long-term functional outcome in TBI patients with moderate anemia.
Although no type of transfusion was significantly Odds of a patient having undergone transfusion and having a lower GOSE score (poor outcome 6 months after injury) relative to the nontransfused group, after adjusting for age, initial injury severity, and serum sodium level. The nontransfused group included patients who did not receive FFP, platelets, or packed RBCs (pRBCs). This figure highlights selected statistically significant odds ratios from Tables 7 and  9 . associated with increased mortality rates, the negative effects on long-term functional outcome are important when considering whether a transfusion will be beneficial or harmful to an individual patient. The low incidence of patient death in this study may partially account for the lack of a statistically significant association between transfusion and mortality. Long-term functional outcome is likely a more sensitive and useful measure of patient outcome than mortality, as long-term disability is a more common consequence of TBI than death. This study was designed to explore the moderate ranges of bleeding diatheses in patients with TBI, ranges in which clinical equipoise existed. As mentioned previously, FFP may benefit TBI patients with severe bleeding diatheses, but it was shown to be harmful in a randomized controlled trial in which few patients had coagulopathy. 7 Our findings in TBI patients with moderate coagulopathy or thrombocytopenia seem to parallel findings of previous studies in that, while both have their risks, FFP transfusions appear to be more hazardous than platelet transfusions. Fewer studies have demonstrated the risks of platelet transfusions, although platelet and FFP transfusions are known to increase risks for complications such as TRALI or TACO. While determining the incidence of complications such as TRALI, TACO, or ARDS would be useful to further elucidate the etiology of transfusion's effect on outcome, such data were not readily available in our study population at the time. We describe these complications to highlight what is already known about the adverse effects of transfusion. Future studies investigating the incidence of these variables in TBI patients with moderate coagulopathy could help further clarify the association between transfusion and poor outcome in specific patients, potentially even linking the two in a more causative role. However, for now, we can only describe an association between certain transfusions and outcome in this specific population. There is still uncertainty regarding the appropriate transfusion thresholds (for example, INR and platelet count) to use when deciding to perform a transfusion in a patient who has suffered a TBI. Many clinical factors go into the decision to perform a transfusion besides laboratory values and the risks of transfusion cannot be ignored. For example, a TBI patient in the ICU who is critically ill, not eating well, and may be on antibiotics is at risk for vitamin K deficiency, which is reflected by a prolonged PPT/INR. Not infrequently, the patient may receive an FFP transfusion rather than vitamin K administration to correct an abnormal laboratory value. This study suggests that transfusions may do more harm than good in TBI patients with only moderate coagulopathy. Therefore, we believe that a restricted transfusion protocol, in the right clinical setting, may be more appropriate in this patient population as transfusions and their associated complications may have detrimental effects on long-term functional outcome.
Transfusion in TBI
In addition to the empirical data regarding transfusion risks, there are multiple theoretical concerns regarding transfusion-related complications in TBI. Platelet and FFP transfusion may have the potential to exacerbate cerebral intravascular coagulation, thus leading to infarction and secondary ischemia. Intravascular coagulation is a universal response to TBI, with intravascular microthrombi being most concentrated in the pericontusional tissue and moderately concentrated within the contusion and ipsilateral hemisphere. 20 In TBI patients who succumb to their injuries, 91% have evidence of cerebral ischemia at autopsy indicating that much of the cerebral damage occurred secondary to the primary traumatic insult. 9, 20 The brain is particularly susceptible to developing intravascular coagulation after injury because it is especially rich in tissue thromboplastin. 12, 20 Traumatic brain injury leads to the release of thromboplastin from damaged tissue, stimulating intravascular coagulation locally in the brain. 2, 20 This process can evolve into DIC if enough thromboplastin is released after a severe injury. 2, 20 In theory, adding platelets or plasma to this situation could exacerbate uncontrolled intravascular coagulation, leading to an expansion of the infarcted area. Despite knowledge of the risks of coagulation disorders and the transfusions intended to treat them, very little research has been done to investigate the net effect of these risks to determine if transfusion is ultimately beneficial or detrimental in TBI. The risk-benefit ratio of transfusion is most likely influenced by the severity of coagulation defects, yet there is still uncertainty about what thresholds of INR, PTT, or platelet count should be used to initiate transfusion. For instance, one study in patients with bleeding diathesis, not TBI, determined that 34% of FFP units were inappropriately transfused due mainly to a lack of awareness of international guidelines and ignorance of risks. 18 The guidelines are generally even less clear in TBI, although traditionally it is suggested that TBI patients receive more liberal transfusion strategies in an attempt to prevent intracranial hemorrhage. Some researchers recommend transfusing platelets at platelet counts less than 100 × 10 9 /L in TBI patients compared with 50 × 10 9 /L in most other patients. 16 Etemadrezaie et al. 7 performed a double-blind randomized controlled trial in 90 patients with severe TBI who were randomized to receive FFP or normal saline for the prevention of delayed traumatic intracerebral hematoma. Not only was delayed traumatic intracerebral hematoma more common in those who received FFP (p = 0.012), but significantly more patients who received FFP died (63.6%) than those who received normal saline (34.8%, p = 0.006).
The causes of death in the FFP group included brain lesion, sepsis, respiratory insufficiency, meningitis, and DIC. One major limitation of this study was that only 4 of the 90 patients actually had a coagulation disorder, defined in that study as a PTT longer than 45 seconds, INR greater than 1.4, or platelet count less than 100 × 10 9 /L. While that study demonstrated that FFP could be harmful in patients who have suffered TBI, the findings cannot be extrapolated to draw conclusions about the net effect of transfusion in TBI patients with moderate to severe coagulation disorders.
Conclusive trials regarding the effects of platelet and plasma transfusions on outcome in TBI patients with moderate coagulation disorders are currently lacking. However, this dilemma of transfusion in patients with moderate hematological abnormality has been addressed by several studies focusing on anemia and RBC transfusion. One of the most influential trials in this area was a multicenter, randomized controlled clinical trial known as the TRICC trial. In this trial, Hébert et al. 10 randomized 838 critically ill patients to either a restrictive or liberal transfusion group. Patients in the restrictive transfusion group were transfused with packed RBCs if the hemoglobin concentration decreased to lower than 7 g/dl and was then maintained at 7-9 g/dl. Patients in the liberal transfusion group were transfused with packed RBCs if hemoglobin concentration decreased to less than 10 g/ dl and was then maintained at 10-12 g/dl. The in-hospital mortality rate was significantly lower in the restrictive transfusion group, suggesting that a restrictive strategy of transfusion was at least as effective if not superior to a liberal transfusion strategy. 10 Although this trial was influential in general critical care, subgroup analysis of 67 patients with closed head injury was unable to detect significant effects of transfusion. 15 Thus, the TRICC trial results may not be generalizable to the TBI population. 24 Anemia in TBI may be especially harmful due to the fact that the injured brain is particularly sensitive to decreases in oxygen delivery and cannot compensate for worsening anemia via autoregulation as well as the uninjured brain. 23 However, many retrospective studies done specifically in the TBI population have shown an association between packed RBC transfusion and increased incidence of complications, lower GOS scores, and a higher mortality rate. 3, 6, 8, 17, 23 Our group investigated the effects of packed RBC transfusion specifically in TBI patients with moderate anemia, defined as having an HCT between 21% and 30%. 24 By analyzing data from 139 patients with TBI who met the criteria for moderate anemia, that study concluded that transfusions may contribute to poor long-term functional outcome, and thus transfusion strategies should be aimed at patients with symptomatic anemia or physiological compromise.
Outcome Measures
The GOSE and FSE were both included as measures of functional outcome as they measure different components of outcome with different theoretical degrees of precision. The FSE could theoretically be a more precise measure of outcome as scores range from 1 to 41 compared with scores ranging from 1 to 8 on the GOSE. Because the GOSE is an older, more widely used established scale, it was our primary outcome measure.
It may be noted that GOSE and FSE correlated with transfusion status to different degrees. Although they are both measures of outcome, GOSE and FSE do not correlate perfectly, as they measure different aspects of impairment. The GOSE measures primarily physical disability (for example, different degrees of motor impairment) whereas the FSE measures physical impairment, cognitive ability, social integration, and ability to care for oneself. Because the FSE measures factors beyond motor function, it may be affected by other impairments (for example, cognitive) that do not affect GOSE, thus resulting in differences between the two outcome measures.
Study Limitations
Although this study suggests an association between certain types of transfusion and outcome, it is not able to show causation. The inability to prove causation stems from several limitations in this study. Although the data were collected prospectively, this is a nonrandomized, retrospective study. Instead of randomization, the study relies on variation in clinical practice to elucidate differences in outcome between patients who received a transfusion and those who did not with similar, moderate degrees of hemostatic abnormalities. We collected data on many types of variables, including patient demographics, initial injury severity measures, and daily laboratory values to include in statistical analysis; however, it is likely that we did not capture all variables influencing clinical transfusion decisions and ultimate outcome. For example, blood pressure values could not be collected in this study, although severe hypotension can greatly influence the decision to perform a transfusion and may lead to further brain injury or death. Because the decision to perform a transfusion depends on other variables besides INR and platelet count, we identified and statistically compensated for potential confounding factors, such as differences in initial GCS score between groups. Although there were no dramatic differences in initial injury severity between the transfusion and nontransfusion groups, the transfusion group represented a slightly sicker group of patients, and the differences between the groups were assessed after including this and other potentially confounding variables in the regression model, as randomization was not possible. Statistically significant initial differences between patients who received a transfusion and those who did not (Table 3) include mean age, number of days of elevated INR, lowest platelet count, number of days of low platelet count, and highest serum sodium. Interestingly, there were no significant differences in initial injury severity (GCS score and ISS), but there were differences in final outcome (GOSE and FSE scores). We do recognize that some differences at baseline likely influenced the decision to perform a transfusion and possibly the final outcome; however, several variables that independently influenced outcome were added to the ordinal regression model to adjust for the influences of these measures. Admittedly, retrospective studies on prospectively collected data cannot replace a randomized controlled trial, and there may be other variables we did not measure that could affect outcome. However, no randomized controlled trials have been performed regarding these issues in patients with moderate coagulopathy, and this study at least calls attention to the potential for poor outcome associated with transfusion. Although we cannot conclude causation due to these limitations, the association between transfusion and poor outcomes in TBI patients with moderate coagulopathy suggests that further investigation is needed to determine the safety of liberal transfusions of FFP. It may be possible that a restrictive FFP transfusion strategy may be beneficial for patients with moderate coagulopathy in the same way that a restrictive RBC transfusion strategy was beneficial in the randomized, controlled TRICC trial.
Although randomized controlled studies remain the gold standard in evidence-based medicine, they are expensive and are not practical in every case of clinical equipoise in a complex condition such as TBI. Despite its limitations, this study in patients with TBI provides insight and caution regarding the effects of transfusion on outcome, which appear to be less benign than previously believed.
Future Directions
Although FFP and, to a lesser degree, platelet transfusions, have been linked to complications such as TRA-LI or TACO, the mechanism by which transfusion can negatively affect neurological outcomes is unclear. Future analysis in a larger population of TBI patients who undergo transfusion could identify what percentage of patients actually suffer from TRALI, TACO, sepsis, DIC, cerebral microinfarctions, or other complications that may be related to transfusion. This information combined with other demographic information would help present a more complete picture of which patient characteristics indicate that transfusion would be beneficial and which characteristics increase risk of transfusion-related complications. More studies will be needed to inform physicians exactly what laboratory values, patient demographics, and other clinical features indicate transfusion will likely be more beneficial than detrimental to patient outcome.
Conclusions
Many factors go into the decision to transfuse a patient who has sustained a TBI, including laboratory values, the severity of the injury, and other individual patient characteristics. More research is needed to fully identify those patients who would be more likely to be harmed by transfusion and the mechanisms by which transfusions * All results were statistically significant; receiving pRBCs alone or in combination with other transfusions resulted in a statistically significant increase in the odds of having a worse outcome in terms of GOSE and FSE score. Odds ratios were adjusted for age, initial injury severity, and serum sodium level.
may hinder neural recovery. However, this study stands as a warning that certain types of transfusions, that of FFP and RBCs, may not be as benign as previously expected. In TBI patients with only moderate coagulation abnormalities, it appears that transfusions lead to worse long-term functional outcome. As in previous studies, this retrospective evaluation is limited in its ability to assess all potential confounding variables related to physiological compromise. A randomized controlled trial investigating transfusion thresholds in TBI patients would be of great value to make more definitive recommendations in this population.
